Etoposide in prostate cancer

Jeffrey M. Kamradt, Kenneth J. Pienta

Research output: Contribution to journalArticlepeer-review

Abstract

Hormone refractory prostate cancer is a disease that kills approximately 39,000 people per year. No single chemotherapeutic agent or regimen has been demonstrated to provide a survival advantage in this disease. Etoposide as a single agent, both in iv. and oral formulations has not proven to be effective. In the 1990s, however, etoposide has been combined with several agents to create novel treatment regimens for patients with hormone refractory disease. Several of these regimens, all involving oral etoposide, have demonstrated promising results in Phase II trials and early results suggest that they may increase survival for hormone refractory patients, although this remains to be tested in a Phase III trial setting. 2000

Original languageEnglish (US)
Pages (from-to)271-275
Number of pages5
JournalExpert opinion on pharmacotherapy
Volume1
Issue number2
DOIs
StatePublished - Jan 1 2000
Externally publishedYes

Keywords

  • Estrannistine
  • Etoposide
  • Hormone refractory prostate cancer
  • Nuclear matrix
  • Oral chemotherapy
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Etoposide in prostate cancer'. Together they form a unique fingerprint.

Cite this